Streetbeat News

Revenues

HOLX

In the past three months, Hologic (NASDAQ:HOLX) received mixed analyst ratings, evolving from a diverse range of perspectives to a more bullish outlook. The average 12-month price target for HOLX has increased to $88.00, reflecting a 7.98% rise from the previous target of $81.50. Analysts from Citigroup, Raymond James, UBS, and Needham have raised their price targets, indicating a positive shift in expectations for Hologic's performance. Despite facing revenue challenges with a -5.69% decline over 3 months, Hologic's financial indicators such as net margin, ROE, and ROA outperform industry standards, suggesting strong financial health and operational efficiency.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:00 pm

AMGN

Analyst ratings for Amgen (NASDAQ:AMGN) show varied opinions over the last quarter, with recent actions including maintaining, raising, and lowering ratings and price targets. The average 12-month price target for AMGN has increased to $328.57, up 7.73% from $305.00. Amgen's financial performance shows solid revenue growth but challenges in net margin and asset utilization. The company's debt-to-equity ratio is higher than the industry average, indicating a reliance on borrowed funds.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:00 pm

SPOT

Spotify Technology S.A. (NYSE:SPOT) shares surged on reports of planned subscription price increases in several key markets, including the UK, Australia, Pakistan, and later in the U.S. The price hike, aimed at covering audiobook costs, is expected to be $1 to $2 per month. Spotify also plans to introduce a new basic subscription excluding audiobooks. Shares were up 5.68% at $284.88.

Portfolio Pulse from Adam Eckert

April 03, 2024 | 2:30 pm

F

SPOT

VGK

Eurozone March inflation showed a decrease, contributing to a positive outlook for the region's economy. Ford reported an increase in electric vehicle (EV) sales, indicating strong demand and growth in the EV sector. Spotify is reportedly raising its prices, which could impact its subscriber growth and revenue.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 2:06 pm

ITCI

In the last three months, 8 analysts have provided diverse ratings for Intra-Cellular Therapies (NASDAQ:ITCI), ranging from bullish to bearish. The average 12-month price target is now $85.88, up 11.9% from the previous $76.75. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their views on the company's performance and market dynamics. Intra-Cellular Therapies, a biopharmaceutical company, has shown a notable revenue growth of 50.41% over the past 3 months but struggles with profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 2:01 pm

AFRM

Affirm Holdings (NASDAQ:AFRM) was analyzed by 7 analysts, showing a consensus towards an indifferent to somewhat bearish outlook with 5 indifferent and 2 somewhat bearish ratings. The 12-month price targets suggest an average of $34.0, marking a 31.78% increase from the previous $25.80 average. Analysts from firms like BMO Capital, JP Morgan, and Goldman Sachs have adjusted their price targets, reflecting a nuanced view on AFRM's financial health and market position. Despite a notable revenue growth of 47.94%, concerns about its net margin, ROE, ROA, and high debt levels persist.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 2:01 pm

RIVN

Recent analysis of Rivian Automotive (RIVN) by 30 financial analysts shows a mix of bullish to bearish sentiments, with a notable shift towards more cautious ratings in the last 30 days. The average 12-month price target for RIVN has been adjusted to $17.07, down from $22.42, reflecting a 23.86% decrease. Analysts' actions range from maintaining current ratings to lowering price targets, indicating a reassessment of Rivian's market position amidst dynamic market conditions. Rivian's financial performance shows a significant revenue growth rate of 98.34% as of December 31, 2023, but challenges in net margin, ROE, and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 2:00 pm

VLO

Valero Energy (NYSE:VLO) has been analyzed by 10 financial analysts, showing a shift towards more bullish sentiments with recent upgrades in ratings and price targets. The average 12-month price target has risen to $174.4, a 14.59% increase from the previous $152.20. Analysts from firms like Barclays, JP Morgan, and UBS have raised their price targets, reflecting optimism about Valero's market position despite a revenue decline of -15.17% in the last quarter. Valero's strong financial indicators such as net margin, ROE, and ROA, alongside a balanced debt approach, contribute to its positive outlook.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 2:00 pm

SAP

SAP (NYSE:SAP) has received mixed analyst ratings over the last three months, with a total of 6 analysts offering views ranging from bullish to bearish. The recent ratings show a shift towards a more positive outlook, with an increase in the average 12-month price target to $200.5, up from $173.33. Analysts from Barclays, BMO Capital, and Goldman Sachs have raised their price targets, reflecting optimism about SAP's market position despite its challenges in revenue growth, net margin, ROE, and ROA compared to industry peers.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 2:00 pm

RVSN

Rail Vision has received a $5M purchase order from Loram, marking a significant business development for the company.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:20 pm